Views
3 years ago

Rounds with the Investigators

Rounds with the Investigators - Research To Practice

POST-TESTRounds with the Investigators: Clinical Research Leaders Consult onChallenging Cases of Early Breast CancerQ ue stions (ple a se circle a nswer):1. Although the Oncotype DX ® assayhas been integrated into the clinicalmanagement of node-negative breastcancer, recent data have emergedsuggesting its potential utility in themanagement of node-positive tumors.a. Trueb. False2. The Oncotype DX assay may be orderedfor ____________ patients with ER- and/or PR-positive breast cancer.a. Premenopausalb. Postmenopausalc. Either pre- or postmenopausal3. T-DM1 is a novel agent that combines amaytansine derivative with __________.a. Docetaxelb. Paclitaxelc. Trastuzumabd. None of the above4. Patients with HER2-positive metastaticdisease previously treated withHER2-directed therapies had a responserate of approximately ___________ withT-DM1.a. Five percentb. 10 percentc. 30 percentd. 60 percent5. In the Phase III NSABP-B-32 trial,patients with clinically node-negativebreast cancer were randomly assigned toundergo sentinel node resection aloneor sentinel node resection followed byaxillary resection.a. Trueb. False6. Phase II and III trials have beencompleted evaluating PARP inhibitors inthe treatment of ________________.a. Triple-negative breast cancerb. BRCA mutation carriersc. HER2-positive breast cancerd. Both a and b7. PARP inhibitors target which of thefollowing?a. Human epidermal growth factorreceptorb. DNA repair mechanismsc. Vascular endothelial growth factord. Epidermal growth factor receptor8. The Southwest Oncology Group isplanning a clinical trial of endocrinetherapy in combination with trastuzumabwith or without ________ for patientswith small, HER2-positive tumors.a. Bevacizumabb. Lapatinibc. Olaparibd. Pertuzumab9. In patients with small T1a or T1btumors, HER2 status _________ significantlyaffect prognosis.a. Doesb. Does not10. The College of American Pathologistsand the American Society of ClinicalOncology joint guidelines on testingfor ER/PR status in breast cancerrecommend that ER assays beconsidered positive if _____ or more oftumor cell nuclei are immunoreactive.a. One percentb. Five percentc. 10 percentd. 15 percent11. The NSABP is planning to conduct aclinical trial evaluating ____________ inpatients with HER2 FISH-negative, IHC1+ or 2+ positive breast cancer.a. Trastuzumabb. Lapatinibc. Both of the aboved. None of the abovePost-test answer key: 1a, 2b, 3c, 4c, 5a, 6d, 7b, 8b, 9a, 10a, 11a4

Educational Assessment and Credit FORMRounds with the Investigators: Clinical Research Leaders Consult onChallenging Cases of Early Breast CancerResearch To Practice is committed to providing valuable continuing education for oncology clinicians,and your input is critical to helping us achieve this important goal. Please take the time to assess theactivity you just completed, with the assurance that your answers and suggestions are strictly confidential.Pa rt O ne — Please tell us about your experience with this educational activityHow would you characterize your level of knowledge on the following topics?4 = Excellent 3 = Good 2 = Adequate 1 = SuboptimalBEFORE AFTERAxillary dissection after negative sentinel lymph node biopsy results 4 3 2 1 4 3 2 1Trastuzumab for subcentimeter, node-negative, HER2-positive tumors 4 3 2 1 4 3 2 1Oncotype DX assay in node-positive breast cancer 4 3 2 1 4 3 2 1Neoadjuvant endocrine therapy for ER-positive disease 4 3 2 1 4 3 2 1Maintaining fertility during chemotherapy 4 3 2 1 4 3 2 1Was the activity evidence based, fair, balanced and free from commercial bias?YesNoIf no, please explain: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Will this activity help you improve patient care?Yes No Not applicableIf no, please explain: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Did the activity meet your educational needs and expectations?YesNoIf no, please explain: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Please respond to the following learning objectives (LOs) by circling the appropriate selection:4 = Yes 3 = Will consider 2 = No 1 = Already doing N/M = LO not met N/A = Not applicableAs a result of this activity, I will be able to:• Apply the results of emerging research in breast cancer clinical managementto treatment and referral strategies for patients with early-stage disease. . . . . . . .4 3 2 1 N/M N/A• Recognize the variability in routine ER, PR and HER2 testing, and implementappropriate guidelines to maximize accurate pathologic assessment. . . . . . . . . . .4 3 2 1 N/M N/A• Develop a treatment plan for patients with HER2-positive breast cancer,considering tumor size and nodal status. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .4 3 2 1 N/M N/A• Effectively utilize biomarkers and genomic risk classifiers to estimate patientprognosis and select or recommend adjuvant therapy. . . . . . . . . . . . . . . . . . . . . .4 3 2 1 N/M N/A• Counsel patients about the value of sentinel lymph node biopsy and itsinfluence on further local and systemic treatment. . . . . . . . . . . . . . . . . . . . . . . . .4 3 2 1 N/M N/A• Recall the design and eligibility criteria for ongoing breast cancer clinical trials,and enroll or refer appropriate patients for study participation. . . . . . . . . . . . . . . .4 3 2 1 N/M N/A5

Rounds with the Investigators - Research To Practice
Conversations with Oncology Investigators
Staff Preference for Multidisciplinary Rounding Practices in the ...
The Principal Investigator's Responsibilities in Research
“Round
Round Bales: A Square Meal? - Kentucky Equine Research
Federal Investigations Practical Pointers
SEC Investigations and Enforcement Actions: A Practical Handbook
The Practice and Pitfalls of Internal Investigations: - Davis Wright ...
The Practice of Crime Scene Investigation - TOP Recommended ...
Investigator-Initiated Research Studiesand Grants Investigator ... - CBI
(single day, practice round) to $200 (season grounds pass)
introduction to investigational drugs - Research - University of ...
ROUND 16 ROUND 17
investigate - CA